首页> 外文期刊>Breast Cancer: Basic and Clinical Research >Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR)
【24h】

Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR)

机译:肿瘤内免疫应答可以区分新的初级和真实复发类型的同侧乳腺肿瘤复发(IBTR)

获取原文
           

摘要

Ipsilateral breast tumor recurrence (IBTR) is an increasingly common clinical challenge. IBTRs include True Recurrences (TR; persistent disease) and New Primaries (NP; de novo tumors), but discrimination between these is difficult. We assessed tumor infiltrating leukocytes (TIL) as biomarkers for distinguishing these types of IBTR using primary tumors and matched IBTRs from 24 breast cancer patients, half of which were identified as putative TRs and half as NPs using a previously reported clinical algorithm. -Intratumoral lymphocyte populations (CD3, CD8, CD4, CD25, FOXP3, TIA1, CD20) and macrophages (CD68) were quantified by immunohistochemistry in each tumor. Compared to matched primaries, TRs showed significant trends towards increased CD3+ and CD8+ TIL, while these populations were often diminished in NPs. Comparison of IBTRs showed that TRs had significantly higher -levels of CD3+ (P = 0.0136), CD8+ (P = 0.0092), and CD25+ (P = 0.0159) TIL than NPs. We conclude that TIL may be a novel diagnostic biomarker to distinguish NP from TR IBTRs.
机译:同侧乳腺肿瘤复发(IBTR)是常见的临床挑战。 IBTRS包括真正的复发(TR;持续性疾病)和新初学者(NP; de Novo肿瘤),但这些歧视是困难的。我们评估了肿瘤浸润的白细胞(直至用于将这些类型的IBTR使用原发性肿瘤和24名乳腺癌患者的IBTR患者区分这些类型的IBTR,其中一半是使用先前报告的临床算法作为NPS被识别为调用TRS。 - 通过每种肿瘤的免疫组化量化 - 通过免疫组织化量量化淋巴细胞群(CD3,CD8,CD4,CD25,FoxP3,Tia1,CD20)和巨噬细胞(CD68)。与匹配的初始相比,TRS显示出CD3 +和CD8 +直至增加的显着趋势,而这些群体通常在NPS中减少。 IBTRS的比较表明,TRS的CD3 +(P = 0.0136),CD8 +(P = 0.0092),CD25 +(P = 0.0159)比NPS显着高于NPS。我们得出结论,TIL可能是一种新型诊断生物标志物,以区分NP从TR IBTRS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号